RVMD News

Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

Revolution Medicines to Participate in November 2025 Investor Conferences

Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025

Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer

Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program

Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer